Browsing Tag
Schizophrenia
20 posts
FDA clears Bysanti and suddenly Vanda Pharmaceuticals Inc has no margin for execution failure
FDA approval of Bysanti sends Vanda Pharmaceuticals Inc stock higher. Read why execution now matters more than hype in schizophrenia and bipolar markets.
Why Teva’s once-monthly olanzapine shot could finally change how schizophrenia is treated in the U.S.
Find out how Teva’s FDA-accepted once-monthly olanzapine injection could reshape schizophrenia care and what investors and clinicians will watch next.
Is biomarker-enriched trial design the key to solving schizophrenia cognition failures?
Can biomarker-enriched trials solve schizophrenia cognition failures? Explore Alto Neuroscience’s strategy and what Phase 2 data could mean next.
Minerva Neurosciences gains up to $200m to advance Roluperidone toward FDA approval and U.S. market launch
Minerva Neurosciences secures up to $200 million to fund a new Phase 3 trial of Roluperidone and prepare for a potential U.S. launch. Find out what’s next.
MapLight Therapeutics sets sights on Nasdaq IPO as CNS pipeline advances toward pivotal trials
MapLight Therapeutics files for Nasdaq IPO to raise $250M for schizophrenia and Alzheimer’s trials. Find out what’s next for this neuroscience innovator.
Phencyclidine: From medical innovation to a declining hallucinogen
Phencyclidine, once developed as an intravenous anaesthetic, quickly fell out of medical use due to its unpredictable and…
Medincell’s Phase 3 trial for long-acting injectable olanzapine in schizophrenia reaches completion
Medincell has announced the successful completion of the pivotal Phase 3 SOLARIS clinical trial for its long-acting injectable…
AbbVie’s schizophrenia treatment crumbles, boosting Bristol Myers Squibb to the top
Bristol Myers Squibb’s stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials…
Alembic Pharmaceuticals secures USFDA approval for new Paliperidone extended-release tablets
Alembic Pharmaceuticals Limited has achieved a major milestone in the pharmaceutical industry. On September 27, 2024, the company…
AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will…